Shares of Veru VERU moved higher by 4.2% in pre-market trading after the company reported Q4 results.
Earnings per share rose 160.00% year over year to $0.03, which beat the estimate of ($0.04).
Revenue of $11,749,000 up by 34.61% year over year, which beat the estimate of $10,630,000.
Veru hasn't issued any earnings guidance for the time being.
Veru hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Dec 09, 2020
Time: 08:00 AM
ET Webcast URL: https://verupharma.com/investors/presentations-conference-calls/
52-week high: $4.74
Company's 52-week low was at $2.10
Price action over last quarter: Up 26.12%
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.